IBDEI1ST ; ; 19-NOV-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,30108,0)
 ;;=Z85.79^^135^1373^94
 ;;^UTILITY(U,$J,358.3,30108,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30108,1,3,0)
 ;;=3^Personal Hx of Malig Neop of Lymphoid,Hematpoetc & Rel Tissue
 ;;^UTILITY(U,$J,358.3,30108,1,4,0)
 ;;=4^Z85.79
 ;;^UTILITY(U,$J,358.3,30108,2)
 ;;=^5063437
 ;;^UTILITY(U,$J,358.3,30109,0)
 ;;=Z85.820^^135^1373^83
 ;;^UTILITY(U,$J,358.3,30109,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30109,1,3,0)
 ;;=3^Personal Hx of Malig Melanoma of Skin
 ;;^UTILITY(U,$J,358.3,30109,1,4,0)
 ;;=4^Z85.820
 ;;^UTILITY(U,$J,358.3,30109,2)
 ;;=^5063441
 ;;^UTILITY(U,$J,358.3,30110,0)
 ;;=Z85.828^^135^1373^98
 ;;^UTILITY(U,$J,358.3,30110,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30110,1,3,0)
 ;;=3^Personal Hx of Malig Neop of Skin
 ;;^UTILITY(U,$J,358.3,30110,1,4,0)
 ;;=4^Z85.828
 ;;^UTILITY(U,$J,358.3,30110,2)
 ;;=^5063443
 ;;^UTILITY(U,$J,358.3,30111,0)
 ;;=Z85.71^^135^1373^78
 ;;^UTILITY(U,$J,358.3,30111,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30111,1,3,0)
 ;;=3^Personal Hx of Hodgkin Lymphoma
 ;;^UTILITY(U,$J,358.3,30111,1,4,0)
 ;;=4^Z85.71
 ;;^UTILITY(U,$J,358.3,30111,2)
 ;;=^5063435
 ;;^UTILITY(U,$J,358.3,30112,0)
 ;;=Z65.8^^135^1373^138
 ;;^UTILITY(U,$J,358.3,30112,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30112,1,3,0)
 ;;=3^Psychosocial Circumstance Related Problems
 ;;^UTILITY(U,$J,358.3,30112,1,4,0)
 ;;=4^Z65.8
 ;;^UTILITY(U,$J,358.3,30112,2)
 ;;=^5063185
 ;;^UTILITY(U,$J,358.3,30113,0)
 ;;=Z86.11^^135^1373^115
 ;;^UTILITY(U,$J,358.3,30113,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30113,1,3,0)
 ;;=3^Personal Hx of Tuberculosis
 ;;^UTILITY(U,$J,358.3,30113,1,4,0)
 ;;=4^Z86.11
 ;;^UTILITY(U,$J,358.3,30113,2)
 ;;=^5063461
 ;;^UTILITY(U,$J,358.3,30114,0)
 ;;=Z86.13^^135^1373^82
 ;;^UTILITY(U,$J,358.3,30114,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30114,1,3,0)
 ;;=3^Personal Hx of Malaria
 ;;^UTILITY(U,$J,358.3,30114,1,4,0)
 ;;=4^Z86.13
 ;;^UTILITY(U,$J,358.3,30114,2)
 ;;=^5063463
 ;;^UTILITY(U,$J,358.3,30115,0)
 ;;=Z86.73^^135^1373^112
 ;;^UTILITY(U,$J,358.3,30115,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30115,1,3,0)
 ;;=3^Personal Hx of TIA & Cereb Infrc w/o Residual Deficits
 ;;^UTILITY(U,$J,358.3,30115,1,4,0)
 ;;=4^Z86.73
 ;;^UTILITY(U,$J,358.3,30115,2)
 ;;=^5063477
 ;;^UTILITY(U,$J,358.3,30116,0)
 ;;=Z86.79^^135^1373^75
 ;;^UTILITY(U,$J,358.3,30116,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30116,1,3,0)
 ;;=3^Personal Hx of Circulatory System Diseases
 ;;^UTILITY(U,$J,358.3,30116,1,4,0)
 ;;=4^Z86.79
 ;;^UTILITY(U,$J,358.3,30116,2)
 ;;=^5063479
 ;;^UTILITY(U,$J,358.3,30117,0)
 ;;=Z91.040^^135^1373^64
 ;;^UTILITY(U,$J,358.3,30117,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30117,1,3,0)
 ;;=3^Latex Allergy Status
 ;;^UTILITY(U,$J,358.3,30117,1,4,0)
 ;;=4^Z91.040
 ;;^UTILITY(U,$J,358.3,30117,2)
 ;;=^5063607
 ;;^UTILITY(U,$J,358.3,30118,0)
 ;;=Z98.89^^135^1373^120
 ;;^UTILITY(U,$J,358.3,30118,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30118,1,3,0)
 ;;=3^Postprocedural States/Hx of Surgery NEC
 ;;^UTILITY(U,$J,358.3,30118,1,4,0)
 ;;=4^Z98.89
 ;;^UTILITY(U,$J,358.3,30118,2)
 ;;=^5063754
 ;;^UTILITY(U,$J,358.3,30119,0)
 ;;=Z92.3^^135^1373^79
 ;;^UTILITY(U,$J,358.3,30119,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30119,1,3,0)
 ;;=3^Personal Hx of Irradiation
 ;;^UTILITY(U,$J,358.3,30119,1,4,0)
 ;;=4^Z92.3
 ;;^UTILITY(U,$J,358.3,30119,2)
 ;;=^5063637
 ;;^UTILITY(U,$J,358.3,30120,0)
 ;;=Z91.120^^135^1373^60
 ;;^UTILITY(U,$J,358.3,30120,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30120,1,3,0)
 ;;=3^Intentional Underdose of Meds d/t Financial Hardship
